ALGERIA: REVIEW OF SAIDAL
Article Abstract:
Saidal, the Algerian pharmaceutical laboratory, expects to make a 1999 turnover of EUR 65.3mn, up 10% from 1998. The net earnings are expected to rise form EUR 11.6mn in 1998 to EUR 13.1mn. Saidal supplies 40% of the Algerian demand for medications, and has undergone an extensive reorganisation program carried out between 1995 and 1998. The lines were rationalised in 1995 - 25% of the product line was outdated, and a marketing department was created with investments in two industrial units. Saidal has undertaken a partnership program with foreign laboratories. As a subcontractor, it makes 45 products which were previously imported. Saidal works with Ram Pharma, Pfizer, Novo Nordisk, Medicuba, Dar Alk Dawa, Rhone Poulenc, Hayat Pharm, Meheco, and Eli Lilly. It also makes products under license for Solvay Pharma. The company has asked its foreign partners to invest locally, and in October 1999 seven joint venture were ratified, representing an investment of EUR 90mn. Rhone Poulenc, Novo-Fabre, Dar Al Dawa, GlaxoWellcome, Pfizer, and GPE signed an agreement and Saidal is continuing negotiations with Novartis, Eli Lilly, and Bayer. Saidal is negotiating with Rhone Poulenc, with which it has proposed making products in Algeria where labour costs are low. These products would then be re-exported.
Publication Name: MOCI
Subject: Business, international
ISSN: 0026-9719
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
ALGERIA: THE MEDICATION MARKET
Article Abstract:
Despite the risk, the major foreign pharmaceutical groups are present on the Algerian market. The legislation makes things difficult, because in order to export to Algeria, foreign companies must set up a local industrial project. SmithKline Beecham, Novo Nordisk, Sanofi and Rhone Poulenc have done this, co-operating with the state-owned company Saidal, or private partners such as IMA and LPA. Some foreign laboratories have grouped together via the European Pharmaceutical Group, which includes 20 laboratories. The Algerian medication market appears to be a buoyant one, especially since the local industry supplies only 20% to 30% of the demand. In 1998, Algeria imported EUR 490mn worth of medications, and EUR 338mn worth of these medications came from France. According to the United Nations Organisation for Industrial development, sales of medications reached about US$ 660mn in 1995-1996. Sales are expected to reach US$ 810mn in 2001 and US$ 930mn in 2005, representing US$ 34 per capita.
Publication Name: MOCI
Subject: Business, international
ISSN: 0026-9719
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
ALGERIA: PFIZER PHARM'S PROJECTS
Article Abstract:
Pfizer Pharm, the Algerian laboratory which is 85% owned by Pfizer France and 15% owned by Saidal is one of the six largest Algerian pharmaceutical laboratories representing US$ 450mn, for a 4.4% market share. Pfizer, via Pfizer Hollande, participated in founding a joint venture with Saidal. Pfizer Hollande holds 85% of this company, named Pfizer Saidal Manufacturing (PSM), and Saidal holds 15%. PSM has a capital stock of US$ 16mn, and is going to build a production plant with 3,600 square metres of floor space. This plant, located at the Alger airport, will produce dry forms and at the beginning it will use only 25% of its production capacity. It is expected to be operational in December 2000.
Publication Name: MOCI
Subject: Business, international
ISSN: 0026-9719
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: FRANCE: POSITIVE REVIEW FOR REFLETS DE FRANCE. EU: THE NEW CARREFOUR
- Abstracts: FRANCE: REVIEW OF THE BUTTER MARKET. FRANCE: ORGANIC PRODUCTS BABIES
- Abstracts: FRANCE: REVIEW OF THE MILK MARKET. FRANCE: SALES OF ORGANIC MILK ARE BOOMING. FRANCE: THE MEAL SUBSTITUTE MARKET
- Abstracts: PAKISTAN: CONSTRUCTION OF HYDROELECTRIC STATIONS. JORDAN: THREE WIND FARMS TO BE BUILT. BOSNIA-HERZEGOVNIA